ArticleTuberculosis and respiratory diseases2021
Recent Trends of Lung Cancer in Korea.
Article in Tuberculosis and respiratory diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 61 citations in OpenAlex.
- Effects of Bojungikki-Tang on immune response and clinical outcomes in NSCLC patients receiving immune checkpoint inhibitors: a randomized pilot study.BMC cancer · 2025Trial
- Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset.Cancer research and treatment · 2024Trial
- A Randomized Phase II Study of Irinotecan Plus Cisplatin with or without Simvastatin in Ever-Smokers with Extended Disease Small Cell Lung Cancer.Cancer research and treatment · 2023Trial
- Trial
- Two-year efficacy of SNK01 plus pembrolizumab for non-small cell lung cancer: Expanded observations from a phase I/IIa randomized controlled trial.Thoracic cancer · 2022Trial
- Effects of combination metformin and nintedanib therapy in a mouse model of irradiation-induced pulmonary fibrosis.Journal of radiation research · 2026Article
- Evaluating Korean Lung-RADS Category 2b: Diagnostic Performance and Interreader Agreement in Lung Cancer Screening.Journal of Korean medical science · 2026Article
- Predicting 5-Year Mortality in Non-Small-Cell Lung Cancer Using the Korean Central Cancer Registry: Model Development and Validation Study.JMIR medical informatics · 2026Article
- Treatment Patterns in Early Stage NSCLC in Asia: Findings From the ELEVATE Study.JTO clinical and research reports · 2026Article
- Molecular epidemiology and outcomes ofTranslational lung cancer research · 2026Article
- Advances and challenges in circulating tumor DNA-based early detection of lung cancer.Translational cancer research · 2025Review
- Treatment intensity-dependent association between the number of oral hypoglycemic agents and insulin use and lung cancer risk in patients with type 2 diabetes.Translational lung cancer research · 2025Article
- A comprehensive analysis of antihypertensive medications and their impact on lung cancer incidence and all-cause mortality: a population-based study in South Korea.Journal of thoracic disease · 2025Article
- Association between Antipsychotic Drug and Survival in Patients with Lung Cancer Treated with Chemoradiotherapy: A Nationwide Korean Cohort Study.Cancer research and treatment · 2025Article
- Adjuvant chemotherapy before osimertinib inTranslational lung cancer research · 2025Article
- Development of an integrated testing strategy using in vitro models to predict lung carcinogenesis.Environmental analysis, health and toxicology · 2025Article
- Mesenchymal Stem Cells Expressing CES1 and Soluble TRAIL Activate CPT-11 and Induce Apoptosis in Lung Cancer Brain Metastatic Lesions.Cancer research communications · 2025Article
- Single-Round LDCT Screening in Men Aged ≥ 70 Years: Prevalence of Pulmonary Nodules and Lung Cancer Detection.Cancers · 2025Article
- Impact of pulmonary tuberculosis on lung cancer screening: a narrative review.Ewha medical journal · 2025Review
- Combination therapy with expanded natural killer cells and atezolizumab exerts potent antitumor immunity in small cell lung cancer.Cancer immunology, immunotherapy : CII · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is one of the leading causes of cancer-related deaths in Korea. Although the smoking rate has decreased over time, the prevalence of lung cancer still remains high. In this study, we reviewed recent trends on the incidence, epidemiology, screening, diagnosis, and treatment of lung cancer in Korea by analyzing data from the national lung cancer registry and recently-published studies. Although approximately 40% of patients with non-small cell lung cancer (NSCLC) were diagnosed as stage IV, the 5-year relative survival rate improved from 11.3% (1993-1995) to 30.2% (2013-2017), possibly due to advances in methods of diagnosis and therapy. In addition, the 2019 implementation of the national lung cancer screening program with low-dose computed tomography may have also contributed to these improvements in survival rates. Recently, molecular diagnosis has become more widely used in the identification of genetic mutations in tissue specimens. Target therapy and immune checkpoint inhibitors have also been successfully used, particularly in cases of advanced NSCLC. In the future, further research on the optimal management of lung cancer remains necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.